Coradini D, Cappelletti V, Miodini P, Ronchi E, Scavone G, Di Fronzo G
Tumori. 1984 Aug 31;70(4):339-44. doi: 10.1177/030089168407000408.
Estrogen (ER) and progesterone (PgR) receptor content was assayed in 290 premenopausal women with primary breast cancer, in order to investigate the influence of endogenous hormones on cytoplasmic receptor concentrations throughout the menstrual cycle, subdivided into four phases of ovarian function (early and late follicular phase, early and late luteal phase). Of the total population, 231 (79.7%) patients were ER positive and 59 (20.3%) were ER negative; 220 (75.9%) were PgR positive and 70 (24.1%) were PgR negative. The percentages of positive cases were almost constant in each phase. No significant difference in mean values of ER concentration was noted throughout the cycle. Instead, the PgR concentration significantly increased from the first to the third phase (P = 0.02) and decreased from the third to the fourth phase (P = 0.01). Our results suggest that ER- and PgR- cases are homogeneously distributed and not influenced by the phase of the cycle. Moreover, they suggest that PgR measurement in the luteal phase, rather than in other phases, prevents the occurrence of false low PgR levels and, at the same time, improves its prognostic significance and response rate to endocrine therapy.
对290例绝经前原发性乳腺癌女性患者进行雌激素（ER）和孕激素（PgR）受体含量检测，以研究内源性激素对整个月经周期细胞质受体浓度的影响，月经周期分为卵巢功能的四个阶段（卵泡早期和晚期、黄体早期和晚期）。在全部人群中，231例（79.7%）患者ER阳性，59例（20.3%）患者ER阴性；220例（75.9%）患者PgR阳性，70例（24.1%）患者PgR阴性。各阶段阳性病例的百分比几乎恒定。整个周期中ER浓度的平均值无显著差异。相反，PgR浓度从第一阶段到第三阶段显著升高（P = 0.02），从第三阶段到第四阶段降低（P = 0.01）。我们的结果表明，ER和PgR病例分布均匀，不受月经周期阶段的影响。此外，结果表明在黄体期而非其他阶段检测PgR可避免出现PgR水平假低的情况，同时提高其预后意义和内分泌治疗反应率。
